Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Avatrombopag in Thrombocytopenic CLD Patients Undergoing Elective Procedure
NCT04915287Phase 4Unknown
- Sponsor
- Chinese PLA General Hospital
- Start
- Jun 2021
- Primary completion
- Jun 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of avatrombopag in Thrombocytopenia (2 arms), sponsored by Chinese PLA General Hospital. Primary endpoint: Proportion of patients not requiring prophylactic platelet transfusion or rescue therapy due to bleeding. Status: unknown.
02
Drugs
avatrombopag
03
Conditions
Thrombocytopenia
Beyond the preview
Go deeper on NCT04915287.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04915287.